Glioblastomas (GBMs) often develop resistance to treatment targeting vascular endothelial growth factor (VEGF) within months of starting therapy.1 Treatment options for tumors that progress despite bevacizumab are limited. This evidence concerns the gene VEGFA and glioblastoma.